Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
Moderna (MRNA) Is Down 5.7% After Costly LNP Settlement And Multi-Pathogen Trial Update - Has The Bull Case Changed?
Moderna’s stock fell 5.7% following a significant LNP settlement requiring an upfront payment of US$950 million and potential further payments, alongside an update on its multi-pathogen mRNA vaccine trial. This settlement secures key LNP rights for Moderna and coincides with a U.S. health advisory committee’s reassessment of mRNA vaccines, highlighting both the financial implications of innovation and potential for broader scientific endorsement. The article examines how these developments, particularly the trial completion, could redefine Moderna’s investment narrative and the future potential of its vaccine platform, emphasizing the need for diversification beyond its COVID-19 franchise.